Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04170296
Other study ID # EN3835-305
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date November 1, 2019
Est. completion date January 8, 2021

Study information

Verified date January 2022
Source Endo Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multicenter, open-label, multiple dose, 2 cohort, Phase 3b study to assess the safety and efficacy of CCH in adult women with mild or moderate edematous fibrosclerotic panniculopathy (EFP). Cohort 1 will include approximately 80 subjects with mild or moderate EFP in the posterolateral thighs and Cohort 2 will include approximately 70 subjects with mild or moderate EFP in the buttocks.


Recruitment information / eligibility

Status Completed
Enrollment 153
Est. completion date January 8, 2021
Est. primary completion date October 6, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: 1. Have both buttocks or both posterolateral thighs with: 1. A score of 2 or 3 (mild or moderate) as reported by the investigator using the Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS). 2. A Hexsel Cellulite Severity Scale (CSS) Subsection D "Grade of Laxity, Flaccidity, or Sagging Skin" score of 0 (absence of laxity, flaccidity, or sagging skin), or 1 (slightly draped appearance) at the Screening Visit only. 2. Be willing to apply sunscreen to the treatment areas before each exposure to the sun for the duration of the study. 3. Be judged to be in good health. 4. Have a negative pregnancy test. 5. Be willing and able to cooperate with the requirements of the study. Exclusion Criteria: 1. Is from a vulnerable population, as defined by the United States (US) Code of Federal Regulations (CFR) Title 45, Part 46, Section 46.111(b) and other local and national regulations, including but not limited to, employees (temporary, part-time, full-time, etc.) or a family member of the research staff conducting the study, or of the sponsor, or of the contract research organization, or of the Institutional Review Board (IRB)/Independent Ethics Committee (IEC). 2. Has a history of sensitivity or allergy to collagenase or any other excipient of CCH. 3. Has systemic conditions (coagulation disorders, malignancy, keloidal scarring, abnormal wound healing) that restricts study participation. 4. Has local (in areas to be treated) conditions (thrombosis, vascular disorder, active infection/inflammation, active cutaneous alteration, tattoo/mole) that restricts study participation. 5. Has skin laxity or linear undulations on the treatment region (both buttocks or both thighs) that can be effaced by lifting skin. 6. Has a Hexsel CSS Subsection D "Grade of laxity, flaccidity, or sagging skin" of 2 (moderate draped appearance) or 3 (severe draped appearance). 7. Requires anticoagulant or antiplatelet medication during the study. 8. Has used or intends to use any of the local applications/therapies/injections/procedures that restricts study participation. 9. Has received any collagenase treatments at any time prior to treatment in this study and/or has received previous treatment with EN3835 or CCH for cellulite. 10. Has received treatment with an investigational product within 30 days (or 5 half-lives, whichever is longer) of the Screening Visit. 11. Is pregnant and/or is providing breast milk in any manner, or plans to become pregnant and/or to provide breast milk during the course of the study. 12. Has any other condition(s) that, in the investigator's opinion, might indicate the subject to be unsuitable for the study.

Study Design


Related Conditions & MeSH terms

  • Cellulite
  • Edematous Fibrosclerotic Panniculopathy (EFP)

Intervention

Drug:
EN3835
Collagenase Clostridium Histolyticum (CCH)

Locations

Country Name City State
Puerto Rico Endo Clinical Trial Site #7 San Juan
United States Endo Clinical Trial Site #10 Alpharetta Georgia
United States Endo Clinical Trial Site #3 Chicago Illinois
United States Endo Clinical Trial Site #1 Coral Gables Florida
United States Endo Clinical Trial Site #2 Encino California
United States Endo Clinical Trial Site #11 Itasca Illinois
United States Endo Clinical Trial Site #12 Nashville Tennessee
United States Endo Clinical Trial Site #8 New Orleans Louisiana
United States Endo Clinical Trial Site #6 New York New York
United States Endo Clinical Trial Site #4 San Diego California
United States Endo Clinical Trial Site #5 Solana Beach California
United States Endo Clinical Trial Site #9 Westport Connecticut

Sponsors (1)

Lead Sponsor Collaborator
Endo Pharmaceuticals

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Proportion of Participants With Improved (+1 or Better) Score on I-GAIS for Either Posterolateral Thigh Investigator Global Aesthetic Improvement Scale (I-GAIS) is a 7-point scale rating global aesthetic improvement in appearance, compared to pretreatment, as judged by the investigator. The rating categories are "Very Much Worse", "Much Worse", "Worse", "No Change", "Improved", "Much Improved", and "Very Much Improved". 90 Days
Primary The Proportion of Participants With Improved (+1 or Better) Score on I-GAIS for Either Buttock Investigator Global Aesthetic Improvement Scale (I-GAIS) is a 7-point scale rating global aesthetic improvement in appearance, compared to pretreatment, as judged by the investigator. The rating categories are "Very Much Worse", "Much Worse", "Worse", "No Change", "Improved", "Much Improved", and "Very Much Improved". 90 Days
Secondary Mean Change From Baseline in CR-PCSS for Each Buttock Clinician-Reported Photonumeric Cellulite Severity Scale (CR-PCSS) is a 5-point photonumeric scale rating cellulite severity from "0" (none) to "4" (severe) from a clinician's perspective. Day 22, 43, 90 and 180
Secondary Mean Change From Baseline in Body Q Appraisal of Cellulite for Posterolateral Thigh Based on Total Score The Body-Q Appraisal of Cellulite is a subset of questions from the Body-Q questionnaire developed to measure participant perceptions of weight loss and/or body contouring. The minimum possible score is 11 and the maximum possible score is 44. Higher scores indicate the individual is less bothered by their cellulite. Copyright Memorial Sloan-Kettering Cancer Center Day 90, Day 180
Secondary Mean Change From Baseline in Body Q Appraisal of Cellulite for Buttock Based on Total Score The Body-Q Appraisal of Cellulite is a subset of questions from the Body-Q questionnaire developed to measure participant perceptions of weight loss and/or body contouring. The minimum possible score is 11 and the maximum possible score is 44. Higher scores indicate the individual is less bothered by their cellulite. Copyright Memorial Sloan-Kettering Cancer Center Day 90, Day 180
Secondary The Proportion of Participants With Improved (+1 or Better) Score on I GAIS for Either Posterolateral Thigh Investigator Global Aesthetic Improvement Scale (I-GAIS) is a 7-point scale rating global aesthetic improvement in appearance, compared to pretreatment, as judged by the investigator. The rating categories are "Very Much Worse", "Much Worse", "Worse", "No Change", "Improved", "Much Improved", and "Very Much Improved". Day 22, 43, and 180
Secondary The Proportion of Participants With Improved (+1 or Better) Score on I-GAIS for Either Buttock Investigator Global Aesthetic Improvement Scale (I-GAIS) is a 7-point scale rating global aesthetic improvement in appearance, compared to pretreatment, as judged by the investigator. The rating categories are "Very Much Worse", "Much Worse", "Worse", "No Change", "Improved", "Much Improved", and "Very Much Improved". Day 22, 43, and 180
Secondary Percentage of Participants With Positive Antibody Titers for Anti-AUX-I and Anti AUX-II (Posterolateral Thigh) Immunogenicity samples with a positive titer value will undergo a log transformation for analyses. Samples with titer level less than 10 were assigned or imputed as a log transformed titer of 1 for analyses Day 1, 90, and 180
Secondary Percentage of Participants With Positive Antibody Titers for Anti-AUX-I and Anti AUX-II (Buttocks) Immunogenicity samples with a positive titer value will undergo a log transformation for analyses. Samples with titer level less than 10 were assigned or imputed as a log transformed titer of 1 for analyses Day 1, 90 and 180
Secondary Presence of Neutralizing Antibody (NAb) Anti AUX-I and AUX-II (Posterolateral Thigh) All the samples with positive ADAs for the participants who had had every other titer levels in the first quartile and fourth quartile of all positive ADAs at Day 90 (performed separately for AUX-I and AUX-II) were tested for NAb. Day 1, 90 and 180
Secondary Presence of NAb Anti AUX-I and AUX-II (Buttocks) All the samples with positive ADAs for the participants who had had every other titer levels in the first quartile and fourth quartile of all positive ADAs at Day 90 (performed separately for AUX-I and AUX-II) were tested for NAb. Day 1, 90 and 180
See also
  Status Clinical Trial Phase
Completed NCT03550157 - Structural Changes of Subcutaneous Tissue by Ultrasonographies in Patients After Treatment With PnKCelulitis® Program
Completed NCT03078647 - Profound Dermal and SubQ Cartridges for the Treatment of Cellulite N/A
Suspended NCT05441917 - Phototherapy and Radiofrecuency for Cellulite N/A
Completed NCT02942160 - EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite) Phase 2
Active, not recruiting NCT02489994 - Performance of the ePrime System for Cellulite N/A
Completed NCT01209767 - Cryolipolysis and Subcision for Treatment of Cellulite N/A
Completed NCT01702259 - Study of the Effect of Low Level Laser Light Therapy on Reducing the Appearance of Cellulite in the Thighs and Buttocks. N/A
Completed NCT04580303 - CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques Phase 2
Completed NCT05358847 - Treatment for Cellulite Appearance N/A
Terminated NCT04209530 - Impact of CCH Treatment of Buttock and Thigh Cellulite in Adult Women Phase 2
Completed NCT05064761 - Safety and Effectiveness of Poly-l-lactic Acid (PLLA) for the Improvement in Appearance of Cellulite N/A
Completed NCT03329989 - Safety and Effectiveness of EN3835 in the Treatment of EFP in Women Phase 2
Completed NCT04419454 - Retrospective Evaluation of Cellulite of Laxity Treatment Using Body Tite
Completed NCT05199506 - Study to Evaluate the Safety and Effectiveness of the RAP Device for the Improvement in the Appearance of Cellulite N/A
Completed NCT05836779 - A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2) Phase 2
Completed NCT05026216 - To Assess the Effectiveness of Multiple Dose, Multiple Concentrations of Qwo, for the Treatment of Mild to Moderate Cellulite. Phase 4
Completed NCT00399854 - Evaluation of the Efficacy of Endermologie in Treatment of Cellulite and Body Contouring Phase 4
Completed NCT00947414 - Cellulite and Extracorporeal Shock Wave N/A
Completed NCT05419505 - Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks Phase 2
Completed NCT03981198 - Proof of Concept (POC) Study of the Soliton Rapid Acoustic (RAP) for the Treatment of Cellulite N/A